Ivosidenib – Another feather in the hat of treatment for acute myeloid leukemia
The treatment of acute myeloid leukemia has undergone a paradigm shift in the past few years. Multiple new targeted and nontargeted agents have been approved in the recent past. Isocitrate dehydrogenase (IDH) mutation is one such target that has been identified, and two new drugs, ivosidenib and ena...
Saved in:
| Main Author: | Jayachandran Perumal Kalaiyarasi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2020-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=4;spage=552;epage=554;aulast=Perumal |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Unraveling Burden of Isocitrate Dehydrogenase Mutations in AcuteMyeloid Leukemia; Clinico-Hematological Correlation and PrognosticRelevance
by: Syeda Hina Abbas, et al.
Published: (2025-05-01) -
Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma
by: J.W. Valle, et al.
Published: (2025-06-01) -
Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast]
by: Zeidan AM, et al.
Published: (2025-07-01) -
IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies
by: Alexander Bray, et al.
Published: (2025-01-01) -
Transformation of Chronic Myeloid Leukemia to Acute Undifferentiated Leukemia: Case Report and Literature Review
by: Oussama Grari, et al.
Published: (2025-04-01)